Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform
27.4.2026 22:25:00 EEST | Business Wire | Press release
Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle.
As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Lithium-ion chemistry presents inherent challenges, including flammability and reliance on constrained global supply chains—issues that become more acute in large-scale energy storage, where higher energy densities considerably increase fire risks, and growing demand across sectors further strains the supply chain and imperils energy sovereignty.
At the same time, the pace of innovation must accelerate because existing battery solutions are not designed to meet the cost, safety, and performance required for today’s infrastructure demands, particularly in urban areas. Permitting restrictions due to fire risks and long delays are the top concerns for energy storage system project developers.
Alsym’s physics-informed AI platform is designed to accelerate battery innovation by fundamentally improving how new chemistries are discovered, developed, and scaled:
- Uses physics-guided AI to narrow an otherwise unmanageable range of possible battery chemistries — rapidly converges on deployable, non-flammable, high-performance battery chemistries rather than exploring candidates in isolation.
- Integrates machine learning with automated, closed-loop experimentation to extract maximum actionable learning from each test, accelerating progress across materials, cell design, and operating conditions beyond traditional trial-and-error approaches.
- Applies continuous electrochemical, materials, and molecular diagnostics and feedback to understand not just how a battery performs, but why—enabling targeted optimization and robust, predictable scaling from lab to prototype to pilot and commercial production.
- Drives AI-optimized system-level end-to-end co-design of materials, cell architecture, and manufacturing processes – ensuring performance, safety, cost and manufacturability are achieved simultaneously at scale.
This innovation platform approach underpins the development of Alsym’s Na-Series and positions the company to rapidly deliver continued innovation as it scales.
The rapid development of Alsym’s Na-Series sodium-ion battery utilized a chemistry that was identified, tested, developed and built in under a year. Na-Series batteries are non-flammable while delivering high performance, affordability, and competitive energy density. By leveraging abundant, widely available materials, the technology also provides a secure and resilient supply chain advantage over conventional lithium-ion solutions.
“The energy transition cannot wait decades for a better answer for energy storage,” said Dr. Kripa Varanasi, Professor of Engineering at MIT and co-founder of Alsym Energy. “What’s required is a fundamentally faster way to turn innovation into infrastructure. The challenge is no longer just discovery – it’s deployment. By integrating physics-informed AI, deep electrochemical expertise, and system-level intelligence across cell architecture, operations and manufacturing, we’ve built a platform that enables continuous innovation and scalable deployment of safer, cost-effective battery technologies for critical infrastructure.”
Na-Series batteries surpass non-flammability tests
From the outset, Alsym set a clear objective: to develop a truly non-flammable and high-performance battery chemistry. The physics-informed AI platform enabled this goal—guiding the discovery and refinement of a system that eliminates the risk of thermal runaway.
Alsym has validated the inherent safety of its chemistry through rigorous testing. In accelerated rate calorimetry (ARC) testing, Na-Series cells were heated from room temperature to 400°C without ever going into thermal runaway. In nail penetration tests conducted on fully charged cells, no rupture, fire, or flame was observed at any point—demonstrating the system’s resistance to catastrophic failure modes that have challenged existing battery technologies. These results underscore the success of Alsym’s platform to deliver real innovation designed to solve a market problem.
“The safety of Na-Series enables deployments everywhere lithium-ion batteries can, and all the places lithium can’t,” said Mukesh Chatter, CEO of Alsym Energy. “The levelized cost of energy (LCOE) advantages are also clear: its wide operating temperature range enables substantial operating cost savings, and upfront costs are very competitive both at the cell and system level. Coupled with fast charge and discharge rates, and flexible use across short, medium and long durations, Alsym Na-Series is a fundamentally better battery for energy storage. For customers, this means lower total cost of ownership, reduced risk, simplified safety and thermal management requirements, broader deployment flexibility, and increased revenue through fast charge–discharge and optimized cycling that captures value from dynamic grid pricing.”
Alsym’s Na-Series batteries support a wide range of applications, including utilities and microgrids, data centers, commercial real estate, industrial operations, maritime environments, defense systems, and residential energy storage. The company is currently advancing its commercialization roadmap and will be shipping cells and modules to strategic partners starting in Q3 2026.
ABOUT ALSYM
Alsym Energy is enabling a safer, scalable energy future by rethinking battery chemistry. The company's flagship Na-Series are non-flammable, high-performance, low cost sodium-ion batteries made with earth abundant materials. They are designed using a proprietary, physics-informed AI platform that enables the discovery of materials and commercially viable chemistries 10x faster than traditional, trial and error experiment-only methods. By combining DeepTech expertise in batteries with physics-informed AI, the platform is a closed-loop system that accelerates the entire battery development process, from ideation to manufacturing. Alsym’s Na-Series technology eliminates thermal runaway and allows energy storage to be deployed safely, and at scale, anywhere energy storage is needed — from data centers and industrial facilities to residential buildings, commercial real estate, mining, military installations or utility grids. Its wide operating temperature range avoids the need for HVAC systems for safety or performance, and fast charge and discharge rates allow multiple cycles per day, creating a powerful economic model for energy storage systems. Alsym Na-Series: A better battery for energy storage.
To learn more, visit: alsym.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260427875189/en/
Contacts
Shiyun Fu
Antenna Group for Alsym
alsym@antennagroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom